New combo therapy targets tough lung cancer gene
NCT ID NCT07294261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (goselasib plus other drugs) as a first treatment for people with advanced or spreading non-small cell lung cancer that has a specific gene change called KRAS G12C. About 69 adults who have not had prior treatment for their advanced cancer will take part. The goal is to see if the combination shrinks tumors and how long the effect lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University
Guangzhou, Guangdong, 510000, China